CBD skin patch for seizures in Dravet and Lennox-Gastaut syndromes
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests a skin patch that delivers CBD (a substance from cannabis) to treat seizures in people with Dravet syndrome or Lennox-Gastaut syndrome. The patch is placed on the skin, and the study looks at whether it is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are between 2 and 55 years old.
- A doctor has confirmed a diagnosis of Dravet syndrome or Lennox-Gastaut syndrome.
- You (or your child) have at least 4 countable seizures in a 28-day period.
- You (or your child) take at least one anti-seizure medication at a stable dose for 4 weeks before starting.
- You (or your child) must not use any cannabis or CBD products for the study period.
- You (or your child) must be generally healthy, without certain medical conditions like diabetes, heart disease, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens when children with Dravet or Lennox Gastaut syndrome switch from a homemade or artisanal CBD product to Epidiolex, a prescription CBD. The goal is to see if the switch is safe and helps control seizures.
This trial tests a new type of brain stimulation (adaptive deep brain stimulation) that adjusts in real time to stop seizures in children with Lennox-Gastaut syndrome. It's for children who haven't gotten enough help from medications and have frequent drop seizures.
This study tests a brain implant that delivers electrical stimulation during sleep to reduce seizures in people with Lennox-Gastaut syndrome. It aims to improve seizure control and sleep quality.
This trial tests whether a reduced, home-based EEG monitoring device can help doctors safely adjust the dose of fenfluramine, a treatment for seizures in Dravet syndrome and Lennox-Gastaut syndrome. Participation may help find the right dose with fewer hospital visits.
This trial tests a way of slowly increasing the dose of a CBD medicine (called Epidiolex) in adults with a severe type of epilepsy called Lennox-Gastaut syndrome (LGS). The goal is to find the best, most comfortable dose that helps reduce seizures.
This study tests whether a cannabis-based medicine can reduce seizures in people with epilepsy that hasn't improved with other treatments. It may offer a new option for those who continue to have seizures.
Hear when a new Lennox Gastaut Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.